|Mr. Mark B. Carbeau||Chief Exec. Officer||414.41k||N/A||57|
|Dr. Kenneth S. Kornman D.D.S., Ph.D.||Co-Founder, Pres, Chief Scientific Officer, Sec. and Director||405.45k||N/A||69|
|Mr. Stephen J. Di Palma M.B.A||Chief Financial Officer||282.63k||N/A||58|
|Mr. Stephan Toutain||Chief Commercial Officer||110.54k||N/A||51|
|Dr. Lynn Doucette-Stamm Ph.D.||VP of Devel. & Clinical Operations||N/A||N/A||N/A|
Interleukin Genetics, Inc. develops and markets proprietary genetic tests for chronic diseases and health-related conditions, and for informing lifestyle choices to facilitate wellness. The company primarily offers cardiovascular risk test; and ILUSTRA Inflammation Management Program, which includes the ILUSTRA genetic risk test to identify individuals with a life-long predisposition to over-produce inflammation. It also provides weight management, bone health, heart health, nutritional needs, and wellness select genetic tests under the Inherent Health brand name. The company markets its tests through healthcare professionals, partnerships with health and wellness companies, and other distribution channels, as well as e-commerce Websites. It has clinical research collaborations with Stanford University, the University of North Carolina, the Mayo Clinic, Brigham & Womens Hospital, University of California, New York University Medical Center, University of Sheffield, Yonsei University Medical Center, Tongji Medical College, University Hospital of Ioannina, and Tufts University Medical Center. The company was founded in 1986 and is headquartered in Waltham, Massachusetts.
Interleukin Genetics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.